AFC-HD AMS Life Science Co. Ltd. said its normalized net income for the fiscal fourth quarter ended Aug. 31 came to ¥17.14 per share, an increase from ¥3.53 per share in the year-earlier period.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥207.6 million, an increase from ¥43.1 million in the year-earlier period.
The normalized profit margin increased to 5.0% from 1.3% in the year-earlier period.
Total revenue climbed 25.1% on an annual basis to ¥4.13 billion from ¥3.31 billion, and total operating expenses increased 17.1% on an annual basis to ¥3.79 billion from ¥3.23 billion.
Reported net income increased from the prior-year period to ¥209.8 million, or ¥17.32 per share, from ¥5.2 million, or 42 sen per share.
For the year, the company's normalized net income totaled ¥46.39 per share, an increase of 76.8% from ¥26.24 per share in the prior year.
Normalized net income was ¥561.9 million, an increase of 77.7% from ¥316.3 million in the prior year.
Full-year total revenue increased 5.0% from the prior-year period to ¥14.41 billion from ¥13.73 billion, and total operating expenses rose on an annual basis to ¥13.46 billion from ¥13.16 billion.
The company said reported net income rose on an annual basis to ¥605.6 million, or ¥50.00 per share, in the full year, from ¥282.9 million, or ¥23.48 per share.
As of Nov. 25, US$1 was equivalent to ¥122.85.